

cpt[®] Assistant

Official source for CPT coding guidance

SPECIAL EDITION: July Update

New COVID-19 Vaccine Codes: July Update

The Current Procedural Terminology (CPT[®]) Editorial Panel (the Panel) has approved three new vaccine administration codes (0091A, 0092A, 0093A) for the Moderna vaccine product to address severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease 2019 [COVID-19]) in pediatric patients aged 6 through 11 years. These codes are to be reported with previously established Moderna vaccine product code 91309. The Panel has also approved an additional vaccine administration code (0113A) that is to be reported with the previously established Moderna vaccine product (91311) for pediatric patients aged 6 months through 5 years.

In addition, the code descriptor language for Moderna vaccine administration code 0094A has been revised to specify the appropriate age for its administration. Lastly, the age for the adult Moderna vaccine product (91301) and its associated vaccine administration codes (0011A, 0012A, 0013A) has been revised from 18 years and older to 12 years and older. These changes are retroactively effective as of June 17, 2022, when the vaccines received emergency use authorization (EUA) from the Food and Drug Administration (FDA).

In order to assist CPT code users in differentiating and appropriately reporting the available vaccine product codes and their affiliated immunization administration codes, the American Medical Association (AMA) established a website (<https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codes>) that features timely updates of

the Panel's actions. The last COVID-19 update was in the *CPT® Assistant Special Edition: June Update* (2022) in which the Pfizer vaccine administration code (0084A) for pediatric patients aged 6 months through 4 years was discussed.

This issue of *CPT® Assistant Special Edition* provides guidance on the appropriate use of the three new Moderna vaccine administration codes (0091A, 0092A, 0093A) for pediatric patients aged 6 through 11 years, as well as the use of Moderna vaccine administration code 0113A for pediatric patients aged 6 months through 5 years. Lastly, the age range change for the Moderna vaccine product code (91301) and its associated vaccine administration codes (0011A, 0012A, 0013A) as well as the change to the descriptor language for vaccine administration code 0094A will be discussed.

Immunization Administration for Vaccines/Toxoids

#● 0091A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; first dose when administered to individuals 6 through 11 years

#● 0092A second dose when administered to individuals 6 through 11 years

#● 0093A third dose when administered to individuals 6 through 11 years

#▲ 0094A booster dose when administered to individuals 18 years and over

▶ (Report 0091A, 0092A, 0093A, 0094A for the administration of vaccine 91309) ◀

▶ (Do not report 0091A, 0092A, 0093A, 0094A in conjunction with 91301, 91306, 91311) ◀

#● 0111A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus (SARS-Co-V-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose

#● 0112A second dose

#● 0113A third dose

▶ (Report 0111A, 0112A, 0113A for the administration of vaccine 91311) ◀

▶ (Do not report 0111A, 0112A, 0113A in conjunction with 91301, 91306, 91309) ◀

Vaccines, Toxoids

#● 91309 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use

▶ (Report 91309 with administration code 0091A, 0092A, 0093A, 0094A) ◀

▶ (Do not report 91309 in conjunction with administration codes 0011A, 0012A, 0013A, 0064A, 0111A, 0112A, 0113A) ◀

#● 91311 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative-free, 25 mcg/0.25 mL dosage, for intramuscular use

▶ (Report 91311 with administration code 0111A, 0112A, 0113A) ◀

►(Do not report 91311 in conjunction with administration codes 0011A, 0012A, 0013A, 0064A, 0091A, 0092A, 0093A, 0094A)◄

Previously established vaccine product code 91309 describes Moderna’s COVID-19 vaccine product booster dose for adult patients aged 18 years and older. This vaccine uses a 50 mcg/0.5 mL dosage concentration. As this dosage is the same dosage that will be used in the primary COVID-19 vaccine series for pediatric patients aged 6 through 11 years, vaccine product code 91309 should be reported with newly established vaccine administration code 0091A for the first dose of the primary series, and with code 0092A for the second dose of the primary series for this age population. Vaccine administration code 0093A should be reported when a third dose is administered to a pediatric patient aged 6 through 11 years who is moderately to severely immunocompromised. The Centers for Disease Control and Prevention (CDC) provides guidance regarding COVID-19 vaccination for this special population at <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html>.

As vaccine product code 91309 will now be used for two distinct age populations, it should be noted that unlike other COVID-19 vaccine administration code descriptors, the descriptors for newly established vaccine administration codes 0091A, 0092A, and 0093A include the age range for which the code(s) should be reported. This information was included to differentiate the codes from code 0094A, which represents the administration of the booster dose for the adult population. The age range was added to the descriptor of code 0094A as well.

Code 0113A describes the vaccine administration of a third dose of Moderna’s vaccine product (91311) for pediatric patients aged 6 months through 5 years who are moderately to severely immunocompromised.

Lastly, the FDA approved the use of Moderna’s adult vaccine product described by code 91301 for patients aged 12 years and older. Previously, this vaccine product had only been approved for patients aged 18 years and older. However, this change did not result in revision to the code descriptor for vaccine product code 91301 or to the descriptors of its associated vaccine administration codes (0011A, 0012A, 0013A), and does not affect how code 91301 should be reported in any way.

As previously noted in the *CPT® Assistant Special Edition: March Update (2022)*, Moderna has implemented safeguard measures for its vaccine vials given that different age groups require different doses for the primary vaccine series and the booster dose (if indicated). Each vaccine product is labeled with a specific color scheme involving not only the cap of the vial, but also the border of the label. A wall chart showing each vial and its associated colors is available at <https://www.fda.gov/media/159306/download>.

As with previous COVID-19 vaccine administration codes, counseling is included as part of the administration visit and should not be reported separately. The physician or other qualified health

care professional (QHP) should exercise clinical judgment to determine whether the administration of the vaccine product is appropriate for a given patient. More information on current guidance from the CDC regarding which patients should receive a COVID-19 vaccines is available at <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines.html>.

Note that vaccine administration codes 0091A, 0092A, 0093A, and 0094A are only intended to be reported with vaccine product code 91309, and vaccine administration code 0113A is only intended to be reported with vaccine product code 91311. Parenthetical notes have been added following the administration and product codes to clarify the appropriate use of these new codes.

To accommodate the new coding structure, Appendix Q was added to the CPT code set. Appendix Q details the vaccine codes, their associated vaccine administration code(s), the vaccine manufacturers and names, the National Drug Code (NDC) labeler product ID, and dosing intervals. Appendix Q was recently re-formatted to also show appropriate age ranges for each vaccine product and the associated vaccine administration codes to assist in providing clarity for the user. The new Moderna vaccine administration codes (0091A, 0092A, 0093A) for pediatric patients aged 6 through 11 years as well as the vaccine administration code (0113A) for pediatric patients aged 6 months through 5 years have been added to Appendix Q.

Additional details on the new vaccine coding structure and other pertinent information provided in multiple special editions of the *CPT® Assistant* for COVID-19 guidance are available at <https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-coding-and-guidance>.

Table 1 is an excerpt from Appendix Q that highlights the Moderna vaccine product codes and vaccine administration codes discussed in this article. Bolded text highlights the changes discussed. Refer to the full text of Appendix Q, which is available at <https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codes>, to keep abreast of additional changes as they occur.

Table 1 Excerpt from Appendix Q: Moderna COVID-19 Vaccine Codes*

Vaccine Code	Vaccine Administration Code(s)	Patient Age
91301 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use	0011A (1st Dose) 0012A (2nd Dose) 0013A (3rd Dose)	12 years and older

Vaccine Code	Vaccine Administration Code(s)	Patient Age
91309 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	0091A (1st Dose) 0092A (2nd Dose) 0093A (3rd Dose)	6 years through 11 years
	0094A (Booster)	18 years and older
91311 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use	0111A (1st Dose) 0112A (2nd Dose) 0113A (3rd Dose)	6 months through 5 years

* Bolded text indicates the code changes discussed in this guidance.

The following clinical examples and procedural descriptions reflect typical clinical scenarios for which these new codes would be appropriately reported.

Clinical Example (0091A)

A parent or guardian of a 7-year-old child seeks immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence-supported guidelines. The parent or guardian is offered and agrees to an intramuscular injection of SARS-CoV-2 vaccine for the child for this purpose.

Description of Procedure (0091A)

The physician or other QHP reviews the patient's chart to confirm that vaccination to decrease the risk of COVID-19 is indicated. Counsel the parent or guardian on the benefits and risks of vaccination to decrease the risk of COVID-19 and obtain consent. Administer the first dose of the COVID-19 vaccine by intramuscular injection. Monitor the patient for any adverse reaction. Update the patient's immunization record (and registry when applicable) to reflect the vaccine administered.

Clinical Example (0092A)

A parent or guardian of a 7-year-old child seeks immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence-supported guidelines. The parent or guardian is offered and agrees to an intramuscular injection of SARS-CoV-2 vaccine for the child for this purpose.

Description of Procedure (0092A)

The physician or other QHP reviews the patient's chart to confirm that vaccination to decrease the risk of COVID-19 is indicated. Counsel the parent or guardian on the benefits and risks of vaccination to decrease the risk of COVID-19 and obtain consent. Administer the second dose of the COVID-19 vaccine by intramuscular injection. Monitor the patient for any adverse reaction. Update the patient's immunization record (and registry when applicable) to reflect the vaccine administered.

Clinical Example (0093A)

A parent or guardian of a 7-year-old child seeks immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence-supported guidelines. The parent or guardian is offered and agrees to an intramuscular injection of SARS-CoV-2 vaccine for the child for this purpose.

Description of Procedure (0093A)

The physician or other QHP reviews the patient's chart to confirm that vaccination to decrease the risk of COVID-19 is indicated. Counsel the parent or guardian on the benefits and risks of vaccination to decrease the risk of COVID-19 and obtain consent. Administer the third dose of the COVID-19 vaccine by intramuscular injection. Monitor the patient for any adverse reaction. Update the patient's immunization record (and registry when applicable) to reflect the vaccine administered.

Clinical Example (0113A)

A parent or guardian of a 1-year-old child seeks immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence-supported guidelines. The parent or guardian is offered and agrees to an intramuscular injection of SARS-CoV-2 vaccine for the child for this purpose.

Description of Procedure (0113A)

The physician or other QHP reviews the patient's chart to confirm that vaccination to decrease the risk of COVID-19 is indicated. Counsel the parent or guardian on the benefits and risks of vaccination to decrease the risk of COVID-19 and obtain consent. Administer the third dose of the COVID-19 vaccine by intramuscular injection. Monitor the patient for any adverse reaction. Update the patient's immunization record (and registry when applicable) to reflect the vaccine administered.

AMA Staff

Leslie W. Prellwitz, MBA, CCS, CCS-P, Managing Editor

Rejina Young, Editorial Assistant

Contributing Staff

Jennifer Bell; Kerri Fei; Karen O'Hara; Andrei G. Besleaga; Keisha Sutton-Asaya

Development and Production Staff

Elizabeth Goodman Duke; Lisa Chin-Johnson; Katharine Dvorak; Paige Downie

Orders: ama-assn.org/subscriptions

AMA website: www.ama-assn.org

The *CPT® Assistant Special Edition* information is designed to provide accurate, up-to-date coding information. We continue to make every reasonable effort to ensure the accuracy of the material presented. However, this publication does not replace the *CPT®* codebook; it serves only as a guide.

©2022 American Medical Association. All rights reserved. No part of this publication may be reproduced in any form without prior written permission of the publisher. *CPT®* is a registered trademark of the American Medical Association.